Patients’ characteristics of the ART long-term cohort at cohort enrolment stratified by previous enrolment in the Infectious Diseases Institute research cohort
| Patients characteristics | Research cohort, n=345 (34.5%) | Clinic patients, n=655 (65.5%) | Overall, n=1000 | p Value |
| Sex, female, n (%) | 242 (70.1) | 377 (57.6) | 619 (61.9%) | <0.001 |
| Age in years, median (IQR) | 45 (40–50) | 46 (41–51) | 45 (40–51) | 0.217 |
| WHO stages 3 and 4 | 320 (93.3) | 549 (84.2) | 869 (87.3) | <0.001 |
| BMI (kg/m2), median (IQR) | 22.4 (19.8–25.0) | 22.4 (19.8–25.6 | 20.3 (18.7–22.7) | 0.354 |
| Hb (g/dL), median (IQR) | 13.4 (12.5–14.4) | 14.5 (13.2–15.9) | 14.1 (12.8–15.5) | <0.001 |
| CD4 count (cells/µL), median (IQR) | 624 (447–773) | 450 (329–612) | 507(363-680) | <0.001 |
| HIV RNA <400 (copies/mL), n (%) | 336 (97.4) | 622 (95.6) | 38 (3.8) | 0.148 |
| Median time on ART (months) (IQR) | 126 (124–129) | 124 (121–127) | 125 (122–128) | <0.001 |
| History of | ||||
| Tuberculosis | 48 (13.9) | 104 (15.9) | 52 (15.2) | 0.411 |
| Cryptococcal meningitis | 36 (10.4) | 23 (3.5) | 59 (5.9) | <0.001 |
| Kaposi’s sarcoma | 5 (1.5) | 26 (4.0) | 31 (3.1) | 0.030 |
| Toxoencephalitis | 8 (2.3) | 5 (0.80) | 13 (1.3) | 0.040 |
| PJP | 5 (1.5) | 7 (1.1) | 12 (1.2) | 0.600 |
| ART type | 0.934 | |||
| First line | 282 (81.7) | 534 (81.5) | 816 (81.6) | |
| Second line | 63 (18.3) | 121 (18.5) | 184 (18.4) | |
| Number of drug substitutions | ||||
| 0 | 74 (21.5) | 84 (12.8) | 158 (15.8) | <0.001 |
| 1–2 | 126 (36.5) | 391 (59.7) | 517 (51.7) | |
| 3–4 | 96 (27.8) | 134 (20.5) | 230 (23.0) | |
| >4 | 49 (14.2) | 46 (7.0) | 95 (9.5) | |
| History of | ||||
| Hypertension | 83 (24.1) | 178 (27.2) | 209 (20.9) | 0.286 |
| Cardiovascular diseases | 15 (4.4) | 34 (5.2) | 10 (1.0) | 0.557 |
| Diabetes | 11 (3.2) | 22 (3.4) | 32 (3.2) | 0.886 |
| Tobacco use | 65 (19.2) | 164 (25.6) | 229 (23.4) | 0.024 |
| Alcohol consumption | 254 (74.9) | 482 (75.3) | 736 (75.2) | 0.894 |
ART, antiretroviral treatment; BMI, body mass index; Hb, haemoglobin; PJP, Pneumocystis jiroveci pneumonia.